Table 11.
Brexpiprazole Dosage and Monitoring
| Guideline | Dose | Patient monitoring parameters | Specific side effects | Specific drug interactions |
|---|---|---|---|---|
| APA | Not recommended | |||
| BAP | Not recommended | |||
| CANMAT | 1–3 mg/d | – | – | – |
| CPG-S | Not recommended | |||
| ICSI | Not recommended | |||
| MPG | Not recommended | |||
| NICE | Not recommended | |||
| RANZCP | Not recommended | |||
| TMAP | Not recommended | |||
| WFSBP | Not recommended |
Abbreviations: –, not reported by guideline; AAPs, atypical antipsychotics; APA, American Psychiatric Association; BAP, British Association of Psychopharmacology; CANMAT, Canadian Network for Mood and Anxiety Disorders; CPG-S, Clinical Practice Guidelines in the Spanish NHS; ICSI, Institute for Clinical Systems Improvement; NICE, National Institute for Health and Care Excellence; RANZCP, Royal Australian and New Zealand College of Psychiatrists; MPG, Maudsley Prescribing Guidelines; TMAP, Texas Medication Algorithm Project; WFSBP, World Federation of Societies of Biological Psychiatry.